SPG11 and hereditary spastic paraplegia: Another study uncovered the therapeutic potential of GSK‐3β pathway inhibition to restore neurodevelopmental defects in hereditary spastic paraplegia (HSP) patients with SPG11 mutations (Mishra et al, 2016).